Rachel Humphrey's most recent trade in Pyxis Oncology Inc was a trade of 36,979 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 31, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 38,741 | 96,805 | - | 0 | Common Stock | |
Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 58,064 | 58,064 | - | 0 | Common Stock | |
Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 236,220 | 236,220 | - | - | Stock Option (Right to Buy) | |
Black Diamond Therapeutics... | Rachel Humphrey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) |